QUALIFYING CONDITIONS
Huntington’s Disease & Medical Marijuana: Pennsylvania & West Virginia Qualifying Condition Guide
CCC serves patients living with Huntington’s disease across Pennsylvania and West Virginia with compassionate, judgment-free evaluations. Our physicians are experienced in working alongside neurologists and movement disorder specialists and can help ensure that any cannabis-based approach is carefully considered given the mixed evidence and documented risk of symptom worsening in this condition.
ABOUT Huntington’s Disease
Huntington’s disease (HD) is a rare, inherited neurodegenerative disorder that progressively affects movement, cognition, and behavior. Symptoms typically appear in a person’s 30s or 40s, though a rarer form, Juvenile Huntington’s disease, can affect children and adolescents. There is currently no cure for HD; treatment focuses on managing symptoms. Pennsylvania and West Virginia both recognize Huntington’s disease as a qualifying condition for medical marijuana. If you or a loved one is living with HD, Compassionate Certification Centers can help you understand your options and determine whether certification may be appropriate as part of your neurological care.
It is important to state clearly at the outset: no cannabis product is FDA-approved to treat Huntington’s disease, and the clinical trial evidence for cannabinoids in HD is limited and mixed, including at least one documented case in which a cannabinoid medication made a core HD symptom worse. This page presents that evidence honestly, rather than presenting cannabis as a proven treatment for chorea or other HD symptoms.
What Is Huntington’s Disease?
HD is caused by an inherited mutation in a single gene. A child of a parent with HD has a 50% chance of inheriting the condition. Symptoms progress gradually over time and generally fall into three categories: movement (involuntary jerking or writhing movements called chorea, muscle rigidity, and impaired coordination), cognitive (difficulty planning, organizing, and processing information), and psychiatric (irritability, depression, and mood changes). An estimated 30,000 people in the United States are living with HD, and roughly 200,000 more are at risk of having inherited the gene from an affected parent.
How Is Huntington’s Disease Diagnosed?
- Neurological and neuropsychological examination assessing motor function, coordination, and cognitive status
- Brain imaging (MRI or CT) to assess structural changes
- Genetic testing to confirm the diagnosis, often accompanied by genetic counseling for the patient and at-risk family members
Huntington's Disease-Related Diagnoses That May Qualify in Pennsylvania and West Virginia
Pennsylvania and West Virginia’s medical marijuana programs recognize Huntington’s disease broadly, along with a range of related and overlapping diagnoses. Conditions that may qualify include:
- Huntington’s Disease (Adult-Onset) — primary diagnosis
- Juvenile Huntington’s Disease
- Westphal Variant (Rigid, Akinetic Early-Onset HD)
- Late-Onset Huntington’s Disease
- Huntington’s Disease-Like 2 (HDL2)
Unsure whether your or your loved one’s diagnosis qualifies? Our certified physicians can review your documentation and help determine eligibility.
Common Symptoms of Huntington's Disease
- Involuntary, jerky movements (chorea)
- Muscle rigidity and impaired coordination or gait
- Speech and swallowing difficulty
- Difficulty planning, organizing, or processing thoughts
- Sleep disturbances and fatigue
- Irritability and mood changes
- Depression
- Suicidal or self-harming thoughts
Huntington’s disease carries a well-documented, elevated risk of depression and suicide. If you or someone you know is having thoughts of suicide or self-harm, please reach out to a mental health professional or a crisis line — in the U.S., you can call or text 988 (the Suicide & Crisis Lifeline) at any time.
Medical Cannabis & Huntington's Disease: What the Research Currently Shows
Cannabinoids have been studied in Huntington’s disease for more than three decades, and the findings are decidedly mixed, including at least one important safety signal showing a cannabinoid medication making chorea worse. This section presents that evidence honestly. It is informational only and does not constitute medical advice.
1. Chorea: Conflicting and Largely Disappointing Trial Results
The first controlled trial of a cannabinoid in HD, conducted in 1991, gave 15 patients oral CBD over six weeks and found no significant effect on chorea severity compared to placebo, though CBD was well tolerated. Later case reports using the synthetic cannabinoid nabilone produced conflicting results: one patient’s chorea significantly worsened after a single dose, while a separate case report described improvement in chorea and irritability with regular use. A subsequent placebo-controlled crossover trial of nabilone in 22 HD patients found no significant improvement in chorea itself, though it did find modest improvement on two secondary behavioral and neuropsychiatric measures, with wide confidence intervals. Based on this trial, the American Academy of Neurology’s evidence-based guideline concluded that nabilone “possibly modestly improves” Huntington’s disease chorea — a cautious, qualified conclusion, not an endorsement of cannabinoids as an effective chorea treatment. A separate crossover trial of nabiximols (Sativex) found no significant effect on HD motor symptoms.
2. The Documented Risk: A Cannabinoid Can Make Chorea Worse
One of the most important findings in this body of research is also one of the most concerning: a published case report described a Huntington’s patient whose choreatic movements significantly worsened after a single dose of nabilone. This is a genuine safety signal, not just a lack of benefit, and it underscores why any cannabinoid use in HD should be closely supervised by a neurologist familiar with the patient’s baseline symptoms, with careful monitoring for symptom worsening.
3. Neuropsychiatric Symptoms: A More Promising, Still Preliminary Signal
Some of the more encouraging findings in HD cannabinoid research relate to neuropsychiatric symptoms — irritability, agitation, and mood — rather than movement symptoms directly. The 2009 nabilone trial found modest improvement on standardized behavioral and neuropsychiatric rating scales, and a small, uncontrolled case series of early-onset HD patients using Sativex, dronabinol, or nabilone reported improvement in dystonia and neuropsychiatric symptoms. These are lower-quality study designs — small samples, unblinded, or wide confidence intervals — and should be interpreted cautiously.
4. A Disease-Specific Caution: Cognitive and Psychiatric Effects
Huntington’s disease itself often involves cognitive decline, depression, irritability, and in some cases psychosis. THC-containing cannabis products can cause sedation, confusion, and, in susceptible individuals, worsened anxiety or psychiatric symptoms — effects that may be more consequential for someone already experiencing HD-related cognitive or psychiatric changes. Patients and caregivers should discuss THC content, dosing, and monitoring carefully with both their neurologist and certifying physician.
5. Preclinical Research: Possible Neuroprotection, Not Yet Established
Separate from symptom management, some animal studies have explored whether cannabinoids might have neuroprotective effects that could theoretically slow HD’s underlying neurodegeneration. This research remains in early animal-model stages and has not been tested in human clinical trials. No cannabinoid product is currently FDA-approved, or established in human research, to slow the progression of Huntington’s disease.
Medical Disclaimer: No cannabis-based product is FDA-approved to treat Huntington’s disease, its chorea, or any of its neuropsychiatric symptoms. Clinical trial evidence for cannabinoids in HD is limited and mixed, and includes a documented case of a cannabinoid medication worsening chorea. The information in this section is provided for general informational purposes only and does not constitute medical advice. Patients should never delay, reduce, or discontinue prescribed Huntington’s disease treatments without consulting their neurologist. Always consult your neurologist, along with a certified medical marijuana physician, before incorporating cannabis into your care plan.
APPLICATION GUIDE
How to Get a Medical Marijuana Card for Huntington’s Disease in Pennsylvania or West Virginia
Both Pennsylvania and West Virginia recognize Huntington’s disease as a qualifying condition. The certification process with CCC is straightforward:
Step 1: Register over the phone or online, next-day appointments are often available.
Step 2: Meet with a certified medical marijuana physician who will review your HD diagnosis, current treatment, and symptom profile to determine whether certification is appropriate.
Step 3: Receive your medical marijuana card and begin purchasing from licensed dispensaries in Pennsylvania or West Virginia.
SOURCES & REFERENCES
The following peer-reviewed publications and clinical guidelines informed the research summary above. All sources are publicly accessible via PubMed or the originating journal. No source should be interpreted as establishing medical cannabis as a proven treatment for Huntington’s disease.
Controlled Trials of Cannabinoids for Chorea
[1] Consroe P, Laguna J, Allender J, et al. (1991). “Controlled clinical trial of cannabidiol in Huntington’s disease.” Pharmacology Biochemistry and Behavior, 40(3), 701–708.
The first controlled cannabinoid trial in HD. Found oral CBD safe and well tolerated but with no significant effect on chorea severity compared to placebo.
[2] Curtis A, Mitchell I, Patel S, Ives N, Rickards H. (2009). “A pilot study using nabilone for symptomatic treatment in Huntington’s disease.” Movement Disorders, 24(15), 2254–2259.
A placebo-controlled crossover trial (n=22) finding no significant effect on chorea itself, but modest improvement on secondary behavioral and neuropsychiatric measures with wide confidence intervals.
[3] López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, et al. (2016). “A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease.” Journal of Neurology, 263(7), 1390–1400.
Found no significant effect of nabiximols (Sativex) on HD motor symptoms in a controlled pilot trial.
[4] Koppel BS, Brust JCM, Fife T, et al. (2014). “Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders.” Neurology, 82(17), 1556–1563.
The American Academy of Neurology’s evidence-based guideline, which characterized nabilone as possibly modestly improving HD chorea based on the Curtis et al. 2009 trial — a cautious, qualified conclusion.
Case Reports & Safety Signals
[5] Müller-Vahl KR, Schneider U, Emrich HM. (1999). “Nabilone increases choreatic movements in Huntington’s disease.” Movement Disorders, 14(6), 1038–1040.
A case report documenting significant worsening of chorea in a patient following a single dose of nabilone — an important safety signal included here for full transparency.
[6] Curtis A, Rickards H. (2006). “Nabilone could treat chorea and irritability in Huntington’s disease.” Journal of Neuropsychiatry and Clinical Neurosciences, 18(4), 553–554.
A single case report describing improvement in chorea and irritability with regular low-dose nabilone — contrasting with the Müller-Vahl case above and illustrating the inconsistency in this evidence base.
[7] Saft C, von Hein SM, Lücke T, et al. (2018). “Cannabinoids for Treatment of Dystonia in Huntington’s Disease.” Journal of Huntington’s Disease, 7(2), 167–173.
An uncontrolled case series of early-onset HD patients using Sativex, dronabinol, or nabilone, reporting improvement in dystonia and neuropsychiatric symptoms. Low-quality study design; hypothesis-generating only.
Consensus & Preclinical Research
[8] National Academies of Sciences, Engineering, and Medicine. (2017). “The Health Effects of Cannabis and Cannabinoids.” National Academies Press.
Consensus report discussing preclinical neuroprotection research in HD animal models and summarizing the American Academy of Neurology’s clinical guideline conclusions.
